Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM) (P3-11.012)

Authors

Christina Liang (ORCID: https://orcid.org/0000-0002-2503-1917)
Dulce Soler-Ferran
H. Jeffrey Wilkins
Robert D. Henderson (ORCID: https://orcid.org/0000-0002-2820-8183)
Merrilee Needham (ORCID: https://orcid.org/0000-0001-6591-1444)
Steven A. Greenberg (ORCID: https://orcid.org/0000-0002-9781-1971)

Institutions

University of Notre Dame (US)
Brigham and Women's Hospital (US)
The University of Queensland (AU)
Murdoch University (AU)
Royal Brisbane and Women's Hospital (AU)
Royal North Shore Hospital (AU)
Fiona Stanley Hospital (AU)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000211798
Primary Topic: Inflammatory Myopathies and Dermatomyositis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM) (P3-11.012)

Christina Liang, Dulce Soler-Ferran, H. Jeffrey Wilkins, Robert D. Henderson et al.

Apr 7, 2025

5 links

Neurology

Inflammatory Myopathies and Dermatomyositis

article

Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM) (P3-11.012)

Christina Liang, Dulce Soler-Ferran, H. Jeffrey Wilkins, Robert D. Henderson, Merrilee Needham, Steven A. Greenberg

April 7, 2025article en

Abstract

No abstract available for this paper.

NeurologyVol. 104(7_Supplement_1)

University of Notre Dame (US), Brigham and Women's Hospital (US), The University of Queensland (AU), Murdoch University (AU), Royal Brisbane and Women's Hospital (AU), Royal North Shore Hospital (AU), Fiona Stanley Hospital (AU)

Openalex Percentile: Top 90%

Inflammatory Myopathies and Dermatomyositis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM) (P3-11.012) — Christina Liang, Dulce Soler-Ferran, et al. · Neurology (2025) | TGRS Research Map | TGRS